Short-Term Rapamycin for Inhibition of Neointima Formation after Balloon-Mediated Aortic Injury in Rats: Is There a Window of Opportunity for Systemic Prophylaxis of Restenosis?
Restricted accessResearch articleFirst published online June, 2005
Short-Term Rapamycin for Inhibition of Neointima Formation after Balloon-Mediated Aortic Injury in Rats: Is There a Window of Opportunity for Systemic Prophylaxis of Restenosis?
To evaluate the efficacy of limited short-term systemic administration of rapamycin to prevent neointimal intimal hyperplasia (NIH) in a double-injury rat model of restenosis.
Methods:
Aortic lesions were induced by perivascular placement of silicone cuffs around the aorta of 36 Lewis rats. After 3 weeks, the cuffs were removed, and the vessels were subjected to secondary balloon injury. Rapamycin (sirolimus) was intravenously administered for 5 days in dosages of 0.5 or 2 mg/kg/d beginning at various time points relative to the balloon injury: (1) days −2 to ±2, (2) days 1 to 5, or (3) days 7 to 11. For each treatment period, 6 rats received the 5-day course of the lower or higher dose of rapamycin. Eight rats served as controls undergoing 2-stage injury without rapamycin treatment. Morphometry and immunohistochemistry were performed at 21 days after angioplasty.
Results:
NIH and intimal α-actin expression were inhibited by both dosages when treatment started 2 days before or 1 day after angioplasty. Results were statistically significant for the lower dose when started 1 day after angioplasty (p < 0.01) and for the higher dose when initiated 2 days before the intervention (p < 0.05). Treatment commencing at 7 days did not reduce NIH in either dosage group.
Conclusions:
In a double-injury rat model, NIH can be inhibited by short-term systemic rapamycin, but suppression of early cell migration and proliferation is pivotal. A limited peri-interventional antiproliferative therapy may be of value as an adjunct to control restenosis after balloon angioplasty and/or stenting.
MorgensternBRGetrajdmanGILaffeyKJ. Total occlusion of the femoropopliteal artery: High technical success rate of conventional balloon angioplasty. Radiology. 1998; 172: 937–940.
2.
CurrierJWFaxonDP. Restenosis after percutaneous transluminal coronary angioplasty: Have we been aiming at the wrong target?J Am Coll Cardiol.1995; 25: 516–520.
3.
HintnerMBehrmannC. Long-term results of angioplasties of pelvic and leg blood vessels [in German]. Rofo. 2000; 172: 775–779.
4.
GlagovS.Intimal hyperplasia, vascular modeling, and the restenosis problem. Circulation. 1994; 89: 2888–2889.
5.
KearneyMPieczekAHaleyL. Histopathology of in-stent restenosis in patients with peripheral artery disease. Circulation. 1997; 95: 1998–2002.
6.
BarthKHVirmaniRFroelichJ. Paired comparison of vascular wall reactions to Palmaz stents, Strecker tantalum stents, and Wallstents in canine iliac and femoral arteries. Circulation. 1996; 93: 2161–2169.
7.
LafontATopolE, eds. Arterial Remodeling: A Critical Factor in Restenosis. Boston: Kluwer Academic Publishers; 1997.
8.
FaxonDP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol.1995; 25: 362–369.
9.
KastratiASchuhlenHHausleiterJ. Restenosis after coronary stent placement and randomization to a 4-week combined antiplatelet or anticoagulant therapy: Six-month angiographic follow-up of the Intracoronary Stenting and Antithrombotic Regimen (ISAR) Trial. Circulation. 1997; 96: 462–467.
10.
BertrandMEMcFaddenEPFruchartJC. Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. J Am Coll Cardiol.1997; 30: 863–869.
11.
BoccuzziSJWeintraubWSKosinskiAS. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). Am J Cardiol.1998; 81: 632–636.
12.
SerruysPWFoleyDPHoflingB. Carvedilol for prevention of restenosis after directional coronary atherectomy: Final results of the European carvedilol atherectomy restenosis (EUROCARE) trial. Circulation. 2000; 101: 1512–1518.
13.
SuzukiTKopiaGHayashiS. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation. 2001; 104: 1188–1193.
14.
FarbAHellerPFShroffS. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation. 2001; 104: 473–479.
15.
VirmaniRFarbAGuagliumiG. Drug-eluting stents: Caution and concerns for long-term outcome. Coron Artery Dis.2004; 15: 313–318.
16.
LiistroFStankovicGDi MarioC. First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: Immediate and long-term clinical and angiographic outcome. Circulation. 2002; 105: 1883–1886.
17.
FändrichFRuhnkeMDresskeB. Tolerance-inducing strategies in transplantation surgery-current status and perspectives. Langenbecks Arch Surg.2004; 389: 60–66.
18.
JahnkeTKarbeUSchäferFK. Characterization of a new double-injury restenosis model in the rat aorta. J Endovasc Ther.2005; 12: 318–331.
19.
CordellJLFaliniBErberWN. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem. 1984; 32: 219–229.
20.
CapronLJarnetJHeudesD. Repeated balloon injury of rat aorta. Arterioscler Thromb Vasc Biol.1997; 17: 1649–1656.
GorskiDHLePageDFPatelCV. Molecular cloning of a diverged homeobox gene that is rapidly down-regulated during the G0/G1 transition in vascular smooth muscle cells. Mol Cell Biol.1993; 13: 3722–3733.
23.
CasscellsWLappiDABairdA. Molecular atherectomy for restenosis. Trends Cardiovasc Med.1993; 3: 235.
24.
LafontAFaxonD. Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials?Cardiovasc Res.1998; 39: 50–59.
25.
MosesJWLeonMBPopmaJJ. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med.2003; 349: 1315–1323.
26.
VirmaniRLiistroFStankovicG. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation. 2002; 106: 2649–2651.
27.
FaxonDP. Systemic drug therapy for restenosis: ‘déjà vu all over again.’Circulation. 2002; 106: 2296–2298.
28.
VezinaCKudelskiASehgalSN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975; 28: 721–726.
29.
SehgalSNBakerHVezinaC. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975; 28: 727–732.
30.
ManciniDPinneySBurkhoffD. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003; 108: 48–53.
31.
SehgalSN. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem. 1998; 31: 335–340.
BurkeSELubbersNLChenYW. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol.1999; 33: 829–835.
34.
GalloRPadureanAJayaramanT. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation. 1999; 99: 2164–2167.
35.
HirosumiJNomotoAOhkuboY. Inflammatory responses in cuff-induced atherosclerosis in rabbits. Atherosclerosis. 1987; 64: 243–254.
36.
MoroiMZhangLYasudaT. Interaction of genetic deficiency of endothelial nitric oxide, gender, and pregnancy in vascular response to injury in mice. J Clin Invest. 1998; 101: 1225–1232.
37.
AkishitaMHoriuchiMYamadaH. Inflammation influences vascular remodeling through AT2 receptor expression and signalling. Physiol Genomics. 2000; 2: 13–20.
38.
WuLIwaiMNakagamiH. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type l receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 2001; 104: 2716–2721.
39.
MarxSOJayaramanTGoLO. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res.1995; 76: 412–417.
UchimuraNPereraGBFujitaniRM. Dose-dependent inhibition of myointimal hyperplasia by orally administered rapamycin. Ann Vasc Surg.2004; 18: 172–177.
42.
BraraPSMoussavianMGriseMA. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation. 2003; 107: 1722–1724.
43.
HausleiterJKastratiAMehilliJ. Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis. The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation. 2004; 110: 790–795.
44.
RodriguezAEAlemparteMRVigoCF. Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial). J Invasive Cardiol.2003; 15: 581–584.
45.
WaksmanRAjaniAEPichardAD. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol.2004; 44: 1386–1392.
46.
LiGChenSJOparilS. Direct in vivo evidence demonstrating neointimal migration of adventitial fibroblasts after balloon injury of rat carotid arteries. Circulation. 2000; 101: 1362–1365.
47.
OparilSChenSJChenYF. Estrogen attenuates the adventitial contribution to neointimal formation in injured rat carotid arteries. Cardiovasc Res.1999; 44: 608–614.
HerreiaVLMakridesSCXieHX. Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein. Nat Med.1999; 5: 1383–1389.
50.
FinnAVGoldHKTangA. A novel rat model of carotid artery stenting for the understanding of restenosis in metabolic disease. J Vasc Res.2002; 39: 414–425.
51.
LeidenfrostJEKhanMFBocKP. A model of primary atherosclerosis and post-angioplasty restenosis in mice. Am J Pathol.2003; 163: 773–778.
52.
Von der ThusenJHFekkesMLPassierR. Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis. Arterioscler Thromb Vasc Biol.2004; 24: 357–362.
